Form SC 13G/A Forma Therapeutics Holdi Filed by: Cormorant Asset Management, LP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Oppenheimer Starts Forma Therapeutics (FMTX) at Outperform
February 17, 2021 6:58 AM ESTOppenheimer analyst Mark Breidenbach initiates coverage on Forma Therapeutics (NASDAQ: FMTX) with a Outperform rating and a price target of $60.00.
The analyst comments "We initiate coverage of Forma Therapeutics, which has assembled an impressive pipeline of targeted therapies for rare diseases... More
